SEQ ID NO:1 Protein Reduces Atherosclerotic Plaque Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Arteriosclerosis, characterized by the accumulation of fat and thickening of blood vessel walls, is difficult to treat and poses a significant risk due to its association with cardiovascular and brain diseases, with existing countermeasures being inadequate in effectively preventing or managing the condition.
Innovation Solution
A pharmaceutical composition comprising a protein with a specific amino acid sequence (SEQ ID NO:1) is developed, which, when administered with a pharmaceutically acceptable carrier, reduces the formation of atherosclerotic plaque and exhibits stability, potentially treating arteriosclerosis without toxicity to the liver or kidneys.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for arteriosclerosis are used, then existing medical conditions can be managed, but the treatment effectiveness is insufficient and quality of life is significantly reduced
Solution Approach 1:
The patent changes the molecular parameter by using a specific peptide sequence (EGT022) with 58 amino acids instead of conventional drugs. This peptide was designed to specifically target and reduce atherosclerotic plaque formation, achieving 57% reduction in low-dose administration and 30% reduction in high-dose administration, thereby improving treatment effectiveness without the harmful side effects of conventional therapies
2Reliability
If high-dose administration of the protein composition is used, then atherosclerotic plaque formation is reduced by 30%, but the cost and complexity of treatment increase
Solution Approach 1:
The patent applies partial action by demonstrating that low-dose administration (5 μg/kg body weight) achieves 57% plaque reduction, which is more effective than high-dose administration (50 μg/kg body weight) achieving only 30% reduction. This inverted dose-response relationship suggests that the peptide works more efficiently at lower doses, simplifying treatment protocols and reducing administration complexity while maintaining high efficacy
Data Source
AI summary
The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.